NASDAQ:ONTX - Onconova Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $7.50
Forecasted Upside: 50.00 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
3 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

^$5.00 As of 07/27/2021 01:00 AM ET

▼ -0.23 (-4.40%)

1 month | 3 months | 12 months

Get New Onconova Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ONTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONTX

^$7.50

▲ +50.00% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for Onconova Therapeutics in the last 3 months. The average price target is $7.50, with a high forecast of $11.00 and a low forecast of $4.00. The average price target represents a 50.00% upside from the last price of $5.00.

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Onconova Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
1 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/4/2020

0 strong buy ratings
1 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/4/2020

0 strong buy ratings
1 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/2/2020

0 strong buy ratings
1 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/31/2020

0 strong buy ratings
1 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/29/2021

0 strong buy ratings
1 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/29/2021

0 strong buy ratings
2 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/28/2021

0 strong buy ratings
2 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/28/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/29/2021	Noble Financial	Reiterated Rating	Buy	$11.00	Low
5/18/2021	Guggenheim	Initiated Coverage	Buy	$4.00	High
12/22/2020	Noble Financial	Upgrade	Market Perform ➝ Outperform		Low
11/13/2020	Maxim Group	Reiterated Rating	Hold		Medium
8/25/2020	Noble Financial	Downgrade	Outperform ➝ Market Perform		Low
8/24/2020	Laidlaw	Downgrade	Buy ➝ Hold		High
8/24/2020	Maxim Group	Downgrade	Buy ➝ Hold		High
8/24/2020	HC Wainwright	Downgrade	Buy ➝ Neutral		N/A
8/13/2020	Noble Financial	Reiterated Rating	Buy	$19.50	High
8/3/2020	Noble Financial	Reiterated Rating	Buy		Low
7/27/2020	HC Wainwright	Reiterated Rating	Buy	$30.00	Medium
6/23/2020	Maxim Group	Initiated Coverage	Buy	$18.75	Medium
6/15/2020	Noble Financial	Reiterated Rating	Buy	$19.50	Medium
5/15/2020	Maxim Group	Upgrade	Hold ➝ Buy	$18.75	High
3/25/2020	HC Wainwright	Reiterated Rating	Buy		High
12/27/2019	Noble Financial	Reiterated Rating	Buy	$19.50	High
11/26/2019	Maxim Group	Downgrade	Buy ➝ Hold		High
10/29/2019	Noble Financial	Reiterated Rating	Buy	$180.00	High
9/9/2019	Maxim Group	Set Price Target	Buy	$120.00	Low
8/12/2019	Maxim Group	Set Price Target	Buy	$120.00	Medium
7/25/2019	Noble Financial	Initiated Coverage	Outperform	$180.00	High
5/14/2019	HC Wainwright	Set Price Target	Buy	$375.00	Medium
5/14/2019	Maxim Group	Reiterated Rating	Buy	$240.00	High
3/26/2019	HC Wainwright	Set Price Target	Buy	$375.00	High
3/25/2019	Maxim Group	Reiterated Rating	Buy	$240.00	Low
2/8/2019	HC Wainwright	Reiterated Rating	Buy	$375.00	Low
12/3/2018	HC Wainwright	Set Price Target	Buy	$375.00	High
12/3/2018	Maxim Group	Set Price Target	Buy	$240.00	High
11/14/2018	HC Wainwright	Set Price Target	Buy	$375.00	High
11/13/2018	Maxim Group	Set Price Target	Buy	$240.00	High
10/11/2018	Maxim Group	Lower Price Target	Buy	$675.00 ➝ $240.00	Medium
9/27/2018	HC Wainwright	Reiterated Rating	Buy	$375.00	Medium
8/14/2018	HC Wainwright	Set Price Target	Buy	$675.00	High
8/14/2018	Maxim Group	Reiterated Rating	Buy	$675.00	High
5/15/2018	HC Wainwright	Set Price Target	Buy	$675.00	High
5/2/2018	Maxim Group	Upgrade	Hold ➝ Buy		Medium
3/26/2018	HC Wainwright	Set Price Target	Buy	$1,800.00	Low
3/26/2018	Maxim Group	Reiterated Rating	Hold		Low
3/9/2018	HC Wainwright	Reiterated Rating	Buy	$1,800.00	Low
3/8/2018	Maxim Group	Reiterated Rating	Hold		Low
3/2/2018	Maxim Group	Reiterated Rating	Hold		Medium
3/1/2018	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$1,350.00 ➝ $1,687.50	Low
1/18/2018	HC Wainwright	Reiterated Rating	Buy	$1,350.00	High
1/17/2018	Maxim Group	Downgrade	Buy ➝ Hold		High
1/4/2018	HC Wainwright	Set Price Target	Buy	$1,350.00	High
12/19/2017	HC Wainwright	Set Price Target	Buy	$1,350.00	High
12/12/2017	HC Wainwright	Set Price Target	Buy	$1,350.00	Medium
11/9/2017	HC Wainwright	Reiterated Rating	Buy		N/A
11/9/2017	Maxim Group	Set Price Target	Buy	$1,350.00	N/A
11/2/2017	Maxim Group	Reiterated Rating	Buy	$1,350.00	N/A
10/9/2017	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$1,350.00	N/A
8/15/2017	Maxim Group	Set Price Target	Buy	$1,350.00	High
7/25/2017	Dawson James	Reiterated Rating	Buy		High
6/6/2017	Maxim Group	Set Price Target	Buy	$1,350.00	Medium
5/15/2017	Maxim Group	Set Price Target	Buy	$1,350.00	Low
4/27/2017	Laidlaw	Initiated Coverage	Buy ➝ Buy	$2,250.00	Low
4/4/2017	Maxim Group	Reiterated Rating	Buy	$1,350.00	High
3/27/2017	Maxim Group	Set Price Target	Buy	$1,350.00	Low
9/26/2016	Maxim Group	Reiterated Rating	Buy	$1,350.00	N/A
8/19/2016	Maxim Group	Reiterated Rating	Buy	$1,350.00	N/A
8/11/2016	Maxim Group	Set Price Target	Buy	$1,350.00	N/A

(Data available from 7/28/2016 forward)

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Today's Range

Now: $5.00

$4.88

$5.21

50 Day Range

MA: $6.59

$0.73

$13.88

52 Week Range

Now: $5.00

$2.85

$28.95

Volume

267,949 shs

Average Volume

2,181,390 shs

Market Capitalization

$78.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Onconova Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Onconova Therapeutics in the last twelve months: Guggenheim, HC Wainwright, Laidlaw, Maxim Group, Noble Financial, and Zacks Investment Research.
View the latest analyst ratings for ONTX.

What is the current price target for Onconova Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Onconova Therapeutics in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 50.0%. Noble Financial has the highest price target set, predicting ONTX will reach $11.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $4.00 for Onconova Therapeutics in the next year.
View the latest price targets for ONTX.

What is the current consensus analyst rating for Onconova Therapeutics?

Onconova Therapeutics currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ONTX, but not buy more shares or sell existing shares.
View the latest ratings for ONTX.

What other companies compete with Onconova Therapeutics?

Other companies that are similar to Onconova Therapeutics include Puma Biotechnology, DURECT, Flexion Therapeutics, 89bio, Neoleukin Therapeutics, Millendo Therapeutics, Fortress Biotech, Celularity, GX Acquisition, Verrica Pharmaceuticals, RedHill Biopharma, Clearside Biomedical, MedAvail, Taiwan Liposome and MEI Pharma.

How do I contact Onconova Therapeutics' investor relations team?

Onconova Therapeutics' physical mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company's listed phone number is 267-759-3680 and its investor relations email address is [email protected] The official website for Onconova Therapeutics is www.onconova.com.